Bravelle

Bravelle is a brand name of urofollitropin, approved by the FDA in the following formulation(s):

BRAVELLE (urofollitropin - injectable; intramuscular, subcutaneous)

• 
  Manufacturer: FERRING
  
  Approval date: May 6, 2002
  
  Strength(s): 75 IU/VIAL ^[RLD]

Has a generic version of Bravelle been approved?

No. There is currently no therapeutically equivalent version of Bravelle available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bravelle. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Bravelle.

See also...

• Bravelle Consumer Information (Wolters Kluwer)
• Bravelle Consumer Information (Cerner Multum)
• Bravelle Advanced Consumer Information (Micromedex)
• Urofollitropin Purified Consumer Information (Wolters Kluwer)
• Urofollitropin Consumer Information (Cerner Multum)
• Fertinorm Hp Advanced Consumer Information (Micromedex)
• Urofollitropin Intramuscular, Subcutaneous, Injection Advanced Consumer Information (Micromedex)